Wuxi Biologics (cayman) Inc. · HKEX:2269
Wuxi Biologics (cayman) — Corporate Update (June 2026)
22 slides from Wuxi Biologics (cayman)'s corporate update, May 31, 2026
Slide 1: Inside Information: Presentation at 2026 Business Update Meeting
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia
Slide 2: Announcement notice and forward-looking statements caution
Further, to ensure that all shareholders and potential investors of the Company have equal and timely access to such information, the Company has included in this announcement the full copy of the Presentation. Shareholders and potential investors of the Company are reminded that the Presentation ma
Slide 3: Innovation-Driven Sustained High Growth: YTD 2026 Business Update
Innovation-Driven Sustained High Growth: YTD 2026 Business Update May 2026 Stock Code: 2269.HK
Slide 4: Forward-Looking Statements; Use of Adjusted Financial Measures
Forward-Looking Statements This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe
Slide 5: Contents
CONTENTS Recent Technology & Development 01 Platform Advancements 02 Business Update 03 Summary
Slide 6: Recent Technology & Development Platform Advancements
Recent Technology & Development 01 Platform Advancements
Slide 7: Recent Advances in Leading Technology Platforms & Development Capabilities
Recent Advances in Leading Technology Platforms & Development Capabilities PatroLab™ Digital twin platform integrating Process Analytical Technology (PAT) & predictive in-silico modeling for real-time & smarter bioprocess analytics, proactive control, and accelerated decision-making. Growing Scienti
Slide 8: Next-Gen Targeted Integration Platform Accelerates Cell Line Development
Next-Gen Targeted Integration Platform Accelerates Cell Line Development WuXiaTM Platform Random Integration Semi-Targeted Integration Targeted Integration Technology Evolution 2010 2019 2025 2.0 3.0 Clone Diversity Clone Stability Historical Current 3,000+ cells screened to < 30 cells screened to a
Slide 9: Case Studies: Higher Titer with Desirable Product Quality
Case Studies: Empowers Complex Molecules to Achieve Higher Titer with Desirable Product Quality Titer Boost on Difficult-to-Express Molecules Quality Improvement on bsAb While Maintaining High Titer for COGS Reduction • #2: an IND-stage bsAb having head- • #3: an IND-stage bsAb having head- • #1: a
Slide 10: Delivers Speed, Productivity, Quality & Stability Across Multiple Modalities
Delivers Speed, Productivity, Quality & Stability Across Multiple Modalities Rapid Adoption Across Multiple • Accelerated development timelines support higher-margin development Modalities offerings • Higher titer & productivity reduce COGS significantly, a win-win for WuXi Bio and clients Others 23
Slide 11: PatroLab: Bioprocess Digital Twin Implementation at WuXi Biologics
PatroLab™: A Platform Solution For Bioprocess Digital Twin Implementation at WuXi Biologics Raman Data Acquisition & Repository Process Knowledge Hub Process Orchestration Interface Raman Spectroscopy Multi-source data integration Model Visualization o In-line process data: OSI PI system o Off-line
Slide 12: Business Update
Business Update 02
Slide 13: Robust New Project Momentum Supports Growth Visibility
Robust New Project Momentum Supports Growth Visibility • Capitalizing on its leading technology, proven execution, and expanding global WuXiBodyTM OMT Platform ADC Platform SDArBodYTM reach, the Company added 69 new integrated projects as of April 30, 2026, reinforcing its role as a partner of choic
Slide 14: Accelerating Business Momentum Across the Integrated Platform
Accelerating Business Momentum Across the Integrated Platform Global MNC A signed MOU: • 16 programs over 2 years Top 3 manufacturing 50%+ YoY in new bi- IND capacity to expand to • IND through PPQs projects each generating & multi-specific projects1 300 in 2027E from 200 • Commercial US$100m+ reven
Slide 15: Bi- & Multi-Specifics Sustain Strong Growth Momentum & Higher Retention
Bi- & Multi-Specifics Sustain Strong Growth Momentum & Higher Retention Bi- & Multi-Specifics Bi- & Multi-Specifics Significantly Higher Complexity in Pipeline Momentum Development & Manufacturing Nearly 20 royalty-bearing Improves Retention projects “R” • Upstream: Imbalanced expression creates • N
Slide 16: Multi-Layer Royalty Framework Enhancing Value Capture
Multi-Layer Royalty Framework Enhancing Value Capture Illustrative examples for royalty economics: (US$ mm) Drug A, net sales/year $1,000 Drug A1 = research services partnership, eligible for sales royalty Sales royalty @ 5% of net drug sales $50 Cell line royalty @ 0.5% of net drug sales 100% volum
Slide 17: Accelerating PCC-to-POC through BioAdvantage
Accelerating PCC-to-POC through BioAdvantage Enhances Early-Stage Client Access & Business Flow • WuXi Bio participates in the BioAdvantage ecosystem as a Development & CMC development & CMC partner, strengthening access to Research Hospital Preclinical • Manufacturing emerging biotech companies Aca
Slide 18: Summary
03 Summary
Slide 19: Three High-Growth Modalities Powering Accelerated Growth
Three High-Growth Modalities Powering WuXi Bio’s Accelerated Growth Bi- & mAbs & ADCs Multi-Specifics Other Proteins • 211 in pipeline, fastest • High growth modality at WuXi • Multiple $billion-dollar growing modality at WuXi Bio Bio franchises in late-stage/CMO • 3 currently in CMO (all high-poten
Slide 20: Unparalleled Capabilities Enabled Clients' Rapid Value Creation
Unparalleled Capabilities Enabled Clients’ Rapid Value Creation Supporting emerging biotechs from formation to rapid multi-billion-dollar value creation: • US biotech focused on TCEs for autoimmune diseases; 100% pipeline supported by WuXi Bio, 2 years from formation to $2b+ valuation • US biotech f
Slide 21: Technology Leadership & Execution Excellence Position WuXi Bio for Accelerating Growth
Technology Leadership & Execution Excellence Position WuXi Bio for Accelerating Growth Continue to expect reported revenue growth of 13 – 17% YoY (16 – 20% excluding FX) • R – robust • D – strong execution on existing development projects & robust new signs Confident in WuXiaTM TrueSite further st
Slide 22: WuXi Biologics
WuXi Biologics Every Biologic Can Be Made | Premier | | | |
WuXi Biologics (Cayman) — Corporate Update (June 2026) on 6ix